Cargando…
Pharmacokinetics and Tolerability of Inhaled Umeclidinium and Vilanterol Alone and in Combination in Healthy Chinese Subjects: A Randomized, Open-Label, Crossover Trial
Inhaled umeclidinium (UMEC) and the combination of inhaled UMEC with vilanterol (UMEC/VI) are approved maintenance treatments for chronic obstructive pulmonary disease in the US and EU. This was a randomized, open-label, three-period crossover, single- and repeat-dose study to assess the pharmacokin...
Autores principales: | Hu, Chaoying, Jia, Jingying, Dong, Kelly, Luo, Linda, Wu, Kai, Mehta, Rashmi, Peng, Jack, Ren, Yan, Gross, Annette, Yu, Hui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4376748/ https://www.ncbi.nlm.nih.gov/pubmed/25816315 http://dx.doi.org/10.1371/journal.pone.0121264 |
Ejemplares similares
-
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial
por: Kelleher, Dennis L., et al.
Publicado: (2012) -
Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium/Vilanterol via a Single Inhaler in Patients with COPD
por: Mehta, Rashmi, et al.
Publicado: (2018) -
Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study
por: Mehta, Rashmi, et al.
Publicado: (2014) -
Pharmacokinetics of fluticasone furoate, umeclidinium, and vilanterol as a triple therapy in healthy volunteers
por: Brealey, Noushin, et al.
Publicado: (2015) -
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial
por: Day, Nicola C., et al.
Publicado: (2020)